On August 11, 2026, Xunming Biotech proudly announced the successful closure of its Series B funding round, amassing a substantial $100 million. This funding initiative was executed in a phased manner. Initially, Granite Asia was the sole investor in the first stage. As the rounds progressed, renowned industry investors took the helm, with HighLight Capital joining in subsequent investments. Moreover, existing shareholders, including Qiming Venture Partners, Matrix Partners China, and Niulili Capital, reaffirmed their confidence by continuing their support. To date, Xunming Biotech's cumulative fundraising efforts have reached nearly $200 million. The fresh capital injected in this round will be predominantly channeled towards the research, development, and extensive training of a cutting-edge generation of biological foundational models. The objective is to bolster these models' proficiency in pivotal tasks such as molecular design, biological structure modeling, and functional forecasting.